Shifting the limits of resuscitation with “CIRD Controlled Integrated Resuscitation Device” (CIRDinnova)
![](https://www.erasmusmc-rdo.nl/wp-content/plugins/js_composer/assets/vc/no_image.png)
Project summary
Only 3% of the patients survive out-of-hospital resuscitation, and only 18% survive in-hospital resuscitation. In order to increase survival, a therapy was developed named CARL: Controlled Automated Reperfusion of the whoLe body. In this project, the technology is further developed from TRL 7 towards TRL 9.
Impact
Bringing the CARL therapy towards the market, resulting in improved survival rates and better quality of life for survivors after resuscitation.
More detailed information
Principal Investigator:
Dinis Dos Reis Miranda
Role Erasmus MC:
Partner
Department:
Project website:
Not available
Funding Agency:
Horizon 2020 Fast Track to Innovation Pilot
![Horizon-2020-logo](https://www.erasmusmc-rdo.nl/wp-content/uploads/2020/05/Horizon-2020-logo.jpg)